CN119053610A - 1,3,4,7-四氢-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氧氮杂卓Bcl-2抑制剂 - Google Patents
1,3,4,7-四氢-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氧氮杂卓Bcl-2抑制剂 Download PDFInfo
- Publication number
- CN119053610A CN119053610A CN202380016422.5A CN202380016422A CN119053610A CN 119053610 A CN119053610 A CN 119053610A CN 202380016422 A CN202380016422 A CN 202380016422A CN 119053610 A CN119053610 A CN 119053610A
- Authority
- CN
- China
- Prior art keywords
- dimethyl
- pyrrolo
- pyrido
- chlorophenyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263267018P | 2022-01-21 | 2022-01-21 | |
| US63/267018 | 2022-01-21 | ||
| PCT/US2023/060944 WO2023141536A1 (en) | 2022-01-21 | 2023-01-20 | 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119053610A true CN119053610A (zh) | 2024-11-29 |
Family
ID=85382827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380016422.5A Pending CN119053610A (zh) | 2022-01-21 | 2023-01-20 | 1,3,4,7-四氢-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氧氮杂卓Bcl-2抑制剂 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11964990B2 (https=) |
| EP (1) | EP4466273A1 (https=) |
| JP (2) | JP7714811B2 (https=) |
| KR (1) | KR20240136972A (https=) |
| CN (1) | CN119053610A (https=) |
| AR (1) | AR128310A1 (https=) |
| AU (1) | AU2023210279A1 (https=) |
| CA (1) | CA3242074A1 (https=) |
| CO (1) | CO2024009334A2 (https=) |
| IL (1) | IL312709A (https=) |
| MX (1) | MX2024008840A (https=) |
| TW (1) | TW202340210A (https=) |
| WO (1) | WO2023141536A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11964990B2 (en) * | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
| CN117820134A (zh) * | 2024-01-10 | 2024-04-05 | 山东盛安贝新材料有限公司南京分公司 | 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018322059C1 (en) | 2017-08-23 | 2024-09-12 | Guangzhou Lupeng Pharmaceutical Company Ltd. | BCL-2 inhibitors |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| KR20220158725A (ko) | 2020-02-24 | 2022-12-01 | 광조우 루펭 파마슈티칼 컴퍼니 엘티디. | Bcl2 억제제를 함유하는 핫 멜트 압출 고체 분산체 |
| US11964990B2 (en) * | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
-
2023
- 2023-01-19 US US18/156,987 patent/US11964990B2/en active Active
- 2023-01-19 TW TW112102814A patent/TW202340210A/zh unknown
- 2023-01-20 AU AU2023210279A patent/AU2023210279A1/en active Pending
- 2023-01-20 WO PCT/US2023/060944 patent/WO2023141536A1/en not_active Ceased
- 2023-01-20 CA CA3242074A patent/CA3242074A1/en active Pending
- 2023-01-20 AR ARP230100132A patent/AR128310A1/es unknown
- 2023-01-20 MX MX2024008840A patent/MX2024008840A/es unknown
- 2023-01-20 KR KR1020247023725A patent/KR20240136972A/ko active Pending
- 2023-01-20 JP JP2024540933A patent/JP7714811B2/ja active Active
- 2023-01-20 CN CN202380016422.5A patent/CN119053610A/zh active Pending
- 2023-01-20 IL IL312709A patent/IL312709A/en unknown
- 2023-01-20 EP EP23707582.5A patent/EP4466273A1/en active Pending
-
2024
- 2024-03-05 US US18/595,898 patent/US20250066388A1/en not_active Abandoned
- 2024-07-15 CO CONC2024/0009334A patent/CO2024009334A2/es unknown
-
2025
- 2025-07-02 US US19/258,642 patent/US20260028356A1/en active Pending
- 2025-07-15 JP JP2025118767A patent/JP2025160251A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240136972A (ko) | 2024-09-19 |
| WO2023141536A1 (en) | 2023-07-27 |
| US11964990B2 (en) | 2024-04-23 |
| JP7714811B2 (ja) | 2025-07-29 |
| IL312709A (en) | 2024-07-01 |
| CO2024009334A2 (es) | 2024-07-18 |
| JP2025160251A (ja) | 2025-10-22 |
| AR128310A1 (es) | 2024-04-17 |
| AU2023210279A1 (en) | 2024-05-23 |
| US20250066388A1 (en) | 2025-02-27 |
| US20260028356A1 (en) | 2026-01-29 |
| EP4466273A1 (en) | 2024-11-27 |
| JP2025504382A (ja) | 2025-02-12 |
| MX2024008840A (es) | 2024-07-25 |
| TW202340210A (zh) | 2023-10-16 |
| US20230234971A1 (en) | 2023-07-27 |
| CA3242074A1 (en) | 2023-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102368948B1 (ko) | Kras 저해 작용을 갖는 환상 펩티드 화합물 | |
| JP2025160251A (ja) | １，３，４，７－テトラヒドロ－２Ｈ－ピロロ［３’，２’：５，６］ピリド［２，３－Ｂ］［１，４］オキサアゼピンＢｃｌ－２阻害剤 | |
| CN112969683A (zh) | O-取代的丝氨酸衍生物制备方法 | |
| CN112533598A (zh) | 大环mcl-1抑制剂和使用方法 | |
| CA3046171A1 (en) | Multicyclic peptides and methods for their preparation | |
| EP3907234B1 (en) | Preparation method for and intermediate of drug-linker for antibody drug conjugate mc-mmaf | |
| WO2015172732A1 (zh) | 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物 | |
| DE69510338T2 (de) | Azirdin-derivate, deren herstellung und verwendung | |
| EP3966226B1 (en) | Masp inhibitory compounds and uses thereof | |
| JPH06501681A (ja) | レトロウイルス・プロテアーゼの阻害剤 | |
| EP1479681A1 (en) | IMIDAZO(1,2-a)PYRIDINE DERIVATIVE | |
| CN102596218B (zh) | 杆菌肽抗生素 | |
| EP2975046A1 (en) | Novel compounds | |
| CN116390742A (zh) | 环状趋化素-9衍生物 | |
| JPH08104684A (ja) | エポキシコハク酸関連化合物 | |
| RU2689381C1 (ru) | Хиральные S-монотерпенилцистеины | |
| KR20260057452A (ko) | 화합물 및 용도 | |
| 권현영 | Stereoselective Synthesis of a Key Intermediate of Antibiotic Rakicidin A | |
| Mondal et al. | Synthesis of allose-templated hydroxyornithine and hydroxyarginine analogs | |
| CN118974059A (zh) | 囊性纤维化跨膜传导调控因子的调节剂 | |
| CN1121410C (zh) | N－甲基－d－苯丙氨酰基－n－[1－[3－[(氨基亚氨基甲基)－氨基]丙基]－3,3－二氟－2－氧代己基]－l－脯氨酰胺的制备方法 | |
| Edagwa | Total synthesis of a virotoxin and analogs for conformational studies | |
| HK1068615A (en) | Imidazo(1,2-a)pyridine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |